Vaccinia immune globulin ameliorates eczema vaccinatum in a murine model of atopic dermatitis
نویسندگان
چکیده
Supplemental Figure Legends 182 Figure S1. Experimental design of VIG treatment using a murine model of EV. Mice 183 were EC sensitized with OVA or saline for 7 weeks followed by inoculation of 10 7 plaque 184 forming units/mouse by skin scarification. Mice were sacrificed after 7 days of VV inoculation 185 and examined for clinical responses, viral load, serum levels of VV antibodies and cytokine 186 production as previously described (Oyoshi et al., 2009). 10 mg/mouse vaccinia immunoglobulin 187 (VIG) (equivalent to human dose 400 mg/kg body weight) or control immunoglobulin (CIG) 188 were administered by intraperitoneal injection on day-1 (prophylaxis), +1 (immediate/early 189 treatment), or +3 (delayed/late treatment) of VV inoculation.
منابع مشابه
Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum
Threats of bioterrorism have renewed efforts to better understand poxvirus pathogenesis and to develop a safer vaccine against smallpox. Individuals with atopic dermatitis are excluded from smallpox vaccination because of their propensity to develop eczema vaccinatum, a disseminated vaccinia virus (VACV) infection. To study the underlying mechanism of the vulnerability of atopic dermatitis pati...
متن کاملProtective murine and human monoclonal antibodies against eczema vaccinatum.
BACKGROUND Eczema vaccinatum is the most common severe pathology associated with smallpox vaccination (vaccinia virus), occurring at high rates among individuals with a previous history of atopic dermatitis (atopic eczema). METHODS Monoclonal antibodies capable of neutralizing vaccinia virus, anti-H3 and anti-B5, were developed as a potential therapy for treatment of human eczema vaccinatum. ...
متن کاملDevelopment of Eczema Vaccinatum in Atopic Mouse Models and Efficacy of MVA Vaccination against Lethal Poxviral Infection
Smallpox vaccine based on live, replicating vaccinia virus (VACV) is associated with several potentially serious and deadly complications. Consequently, a new generation of vaccine based on non-replicating Modified vaccinia virus Ankara (MVA) has been under clinical development. MVA seems to induce good immune responses in blood tests, but it is impossible to test its efficacy in vivo in human....
متن کاملRisks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963–1968
BACKGROUND The United States (US) has re-instituted smallpox vaccinations to prepare for an intentional release of the smallpox virus into the civilian population. In an outbreak, people of all ages will be vaccinated. To prepare for the impact of large-scale ring and mass vaccinations, we conducted a systematic review of the complication and mortality risks of smallpox vaccination. We summariz...
متن کاملSusceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.
BACKGROUND Patients, especially young children, with atopic dermatitis are at an increased risk of developing eczema vaccinatum, a severe reaction to the smallpox vaccine, either through direct vaccination or indirect contact with a person recently vaccinated. METHODS Using a mouse model of infection, the severity of vaccinia-induced lesions was assessed from their appearance and viral DNA co...
متن کامل